logo

Seasonal Affective Disorder Therapeutics Market Size (2024 - 2029)

The seasonal affective disorder therapeutics market is anticipated to experience growth driven by an increasing prevalence of the condition and enhanced initiatives from key market players. The COVID-19 pandemic significantly influenced the market, initially reducing patient visits but later increasing demand for therapeutics due to rising depression rates. Post-pandemic, the market is expected to expand as more individuals seek treatment for seasonal affective disorder, particularly during winter. Despite these growth drivers, challenges such as a lack of awareness and potential side effects may hinder market expansion.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research External Condition Drugs Research Seasonal Affective Disorder Therapeutics Market Market Size

Market Size of Seasonal Affective Disorder Therapeutics Industry

Seasonal Affective Disorder Therapeutics Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 5.90 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Seasonal Affective Disorder Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Seasonal Affective Disorder Therapeutics Market Analysis

The seasonal affective disorder therapeutics market is expected to register a CAGR of 5.9% during the forecast period.

  • COVID-19 significantly impacted the studied market. The onset of the pandemic led to a reduction in patient visits and fewer patients seeking seasonal affective disorder treatment, affecting market growth. As the pandemic progressed, depression rates rose due to pandemic-related fears. According to a June 2021 study published in the World Journal of Psychiatry, COVID-19 had a significant impact on global daily life. The outbreak was predicted to have a lasting influence on mental health, posing worldwide challenges. The increased depressive symptoms during the pandemic created a demand for therapeutics in the late pandemic stages, positively impacting market growth in the following years. Furthermore, post-pandemic, the market is expected to grow at a significant pace as people feel less energetic, motivated, and chipper in seasons such as winter, thereby leading to increased adoption of seasonal affective disorder (SAD) therapeutics.
  • Certain factors that are driving the market growth include the increasing prevalence of seasonal affective disorder and depression, growing R&D activities, and the rising number of treatment options.
  • The rising prevalence of SAD is expected to drive the market growth. For instance, according to the National Health Service, United Kingdom update in January 2023, the winter blues, also known as seasonal affective disorder (SAD), is estimated to affect more than 12 million people in northern Europe and about 2 million people in the UK and people of all ages, including children, are susceptible to SAD. Such a high prevalence of SAD in developed nations is anticipated to drive market growth due to increased adoption of SAD therapeutics.
  • Furthermore, according to the Anxiety and Depression Foundation facts and statistics updated in June 2022, generalized anxiety disorder affects 6.8 million adults or 3.1% of the United States population per year. Thus, such huge cases of depression and SADs across the world are expected to drive the overall growth of the studied market over the forecast period.
  • Rising initiatives from the key market players, such as partnership and approval of therapies for SAD, are expected to drive the market growth over the forecast period. For instance, in March 2022, Sun Pharmaceutical Industries Limited entered into an exclusive patent licensing agreement with H. Lundbeck A/S to market and distribute its own version of Vortioxetine in India under the brand name VORTIDIF. In addition, in February 2022, Granules India received approval from the United States Food and Drugs Administration for Bupropion Hydrochloride to treat SAD. Such partnerships and approvals lead to increased market availability of SAD therapeutics, driving market growth.
  • Therefore, the rising prevalence of SAD and the rising initiatives from the market players for the launch of drugs for SAD are the factors expected to drive market growth. However, lack of awareness across the regions, probable side effects, and risks are the major factors hindering the seasonal affective disorder therapeutics market's growth.

Seasonal Affective Disorder Therapeutics Industry Segmentation

As per the scope of the report, seasonal affective disorder refers to a mood disorder characterized by depression that occurs at the same time every year. Seasonal affective disorder occurs in climates where there is less sunlight at certain times of the year. Symptoms include fatigue, depression, hopelessness, and social withdrawal. The report covers the several types of drugs used to treat these disorders. 

The seasonal affective disorder therapeutics market is segmented by drug type (selective serotonin reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, monoamine oxidase inhibitors, other drug types), disorder type (unipolar disorder, bipolar disorder), distribution channel (institutional sales, retail sales), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. 

The report offers the market size and forecasts in value (USD) for the above segments.

By Drug Type
Selective Serotonin Reuptake Inhibitors (SSRI)
Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)
Monoamine Oxidase Inhibitor (MAOI)
Other Drug Types
By Disorder Type
Unipolar Disorder
Bipolar Disorder
By Distribution Channel
Institutional Sales
Retail Sales
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Seasonal Affective Disorder Therapeutics Market Size Summary

The seasonal affective disorder (SAD) therapeutics market is poised for significant growth, driven by the increasing prevalence of SAD and depression, alongside rising research and development activities. The market's expansion is further supported by the growing number of treatment options available. The COVID-19 pandemic initially hindered market growth due to reduced patient visits, but it later spurred demand for therapeutics as depression rates rose. This trend is expected to continue post-pandemic, as individuals experience decreased energy and motivation during winter months. Key market players are actively engaging in partnerships and obtaining regulatory approvals to enhance the availability of SAD therapeutics, which is anticipated to further propel market growth. However, challenges such as lack of awareness and potential side effects remain significant barriers to market expansion.

North America holds a substantial share of the SAD therapeutics market, with expectations of continued growth due to the high prevalence of SAD and strategic initiatives by major market players. The region's market expansion is fueled by the increasing adoption of SAD therapeutics and the approval of new drugs by regulatory agencies. The demand for therapeutic drugs is expected to rise, particularly in the United States, where the number of individuals experiencing depressive symptoms has increased since the onset of the COVID-19 pandemic. The market is moderately competitive, with major players like AbbVie Inc., Pfizer Inc., and Eli Lilly and Company leading the charge through the launch of antidepressant drugs and novel therapies. These dynamics, coupled with regulatory changes and approvals, are set to bolster the market's growth trajectory over the forecast period.

Explore More

Seasonal Affective Disorder Therapeutics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Prevalence of Seasonal Affective Disorder and Depression

      2. 1.2.2 Growing R&D Activities and Rising Number of Treatment Options

    3. 1.3 Market Restraints

      1. 1.3.1 Lack of Awareness Across Regions

      2. 1.3.2 Probable Side Effects and Risks

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Drug Type

      1. 2.1.1 Selective Serotonin Reuptake Inhibitors (SSRI)

      2. 2.1.2 Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)

      3. 2.1.3 Monoamine Oxidase Inhibitor (MAOI)

      4. 2.1.4 Other Drug Types

    2. 2.2 By Disorder Type

      1. 2.2.1 Unipolar Disorder

      2. 2.2.2 Bipolar Disorder

    3. 2.3 By Distribution Channel

      1. 2.3.1 Institutional Sales

      2. 2.3.2 Retail Sales

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Seasonal Affective Disorder Therapeutics Market Size FAQs

The Global Seasonal Affective Disorder Therapeutics Market is projected to register a CAGR of 5.90% during the forecast period (2024-2029)

AbbVie Inc. , Eli Lilly and Company , Teva Pharmaceuticals USA, Inc. , Pfizer Inc. and GlaxoSmithKline plc. are the major companies operating in the Global Seasonal Affective Disorder Therapeutics Market.

Seasonal Affective Disorder Therapeutics Market Report Snapshots

Seasonal Affective Disorder Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)